{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:40:59Z","timestamp":1790624459777,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T00:00:00Z","timestamp":1539907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Merrimack Pharmaceuticals, Inc."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ejca.2018.09.029","type":"journal-article","created":{"date-parts":[[2018,11,17]],"date-time":"2018-11-17T06:25:23Z","timestamp":1542435923000},"page":"24-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin"],"prefix":"10.1016","volume":"106","author":[{"given":"Richard A.","family":"Hubner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cubillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Melisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Von Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Wang-Gillam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Tzong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Mamlouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Belanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoojung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris A.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens T.","family":"Siveke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2018.09.029_bib1","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.ejca.2018.09.029_bib2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12029-015-9724-1","article-title":"A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs","volume":"46","author":"Carrato","year":"2015","journal-title":"J Gastrointest Cancer"},{"issue":"16","key":"10.1016\/j.ejca.2018.09.029_bib3","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.3748\/wjg.v21.i16.4788","article-title":"Metastatic pancreatic cancer: is there a light at the end of the tunnel?","volume":"21","author":"Vaccaro","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejca.2018.09.029_bib4","series-title":"SEER statistical fact sheets: pancreas cancer","author":"National Cancer Institute","year":"2016"},{"issue":"4","key":"10.1016\/j.ejca.2018.09.029_bib5","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/annonc\/mdw022","article-title":"European cancer mortality predictions for the year 2016 with focus on leukaemias","volume":"27","author":"Malvezzi","year":"2016","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2018.09.029_bib6","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2018.09.029_bib7","first-page":"326","article-title":"Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience","volume":"3","author":"Malik","year":"2012","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ejca.2018.09.029_bib8","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.9636","article-title":"Metastatic pancreatic cancer: ASCO clinical practice guideline update","author":"Sohal","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.ejca.2018.09.029_bib9","doi-asserted-by":"crossref","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","article-title":"Cancer of the pancreas: ESMO Clinical Practice\u00a0Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Ducreux","year":"2015","journal-title":"Ann Oncol"},{"issue":"suppl_4","key":"10.1016\/j.ejca.2018.09.029_bib10","first-page":"iv157","article-title":"Appendix 6: cancer of the pancreas: MCBS eUpdate published\u00a0online 20 June 2017","volume":"28","year":"2017","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2018.09.029_bib11","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1158\/1078-0432.CCR-16-1990","article-title":"Correlation between ferumoxytol uptake in tumor lesions by MRI and response to nanoliposomal irinotecan in patients with advanced solid tumors: a pilot study","volume":"23","author":"Ramanathan","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2018.09.029_bib12","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/annonc\/mdt002","article-title":"A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma","volume":"24","author":"Roy","year":"2013","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2018.09.029_bib13","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1158\/0008-5472.CAN-14-0572","article-title":"Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion","volume":"74","author":"Kalra","year":"2014","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ejca.2018.09.029_bib14","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCRESAHA.110.226613","article-title":"The critical role of neutral cholesterol ester hydrolase 1 in cholesterol removal from human macrophages","volume":"107","author":"Igarashi","year":"2010","journal-title":"Circ Res"},{"issue":"10018","key":"10.1016\/j.ejca.2018.09.029_bib15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2018.09.029_bib16","series-title":"ONIVYDE 5 mg\/ml concentrate for solution for infusion","author":"Baxalta Innovations GmbH","year":"2016"},{"key":"10.1016\/j.ejca.2018.09.029_bib17","series-title":"US NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) pancreatic adenocarcinoma Version 1.2018","first-page":"1","author":"NCCN U","year":"2018"},{"issue":"5","key":"10.1016\/j.ejca.2018.09.029_bib18","doi-asserted-by":"crossref","first-page":"e0125350","DOI":"10.1371\/journal.pone.0125350","article-title":"Sequential FOLFIRI.3 + gemcitabine improves health-related quality of life deterioration-free survival of patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial","volume":"10","author":"Anota","year":"2015","journal-title":"PLoS One"},{"issue":"32","key":"10.1016\/j.ejca.2018.09.029_bib19","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1200\/JCO.2016.68.5776","article-title":"PANCREOX: a randomized phase III study of fluorouracil\/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy","volume":"34","author":"Gill","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.029_bib20","series-title":"The EORTC QLQ-C30 scoring manual","author":"Fayers","year":"2001"},{"issue":"1","key":"10.1016\/j.ejca.2018.09.029_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2018.09.029_bib22","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejca.2004.10.017","article-title":"Quality of life committee of the NC. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of the national cancer institute of Canada clinical trials group","volume":"41","author":"Osoba","year":"2005","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2018.09.029_bib23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/0962280212448721","article-title":"Longitudinal data analysis with non-ignorable missing data","volume":"25","author":"Tseng","year":"2016","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"10.1016\/j.ejca.2018.09.029_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2012.44.4869","article-title":"Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4\/ACCORD 11 randomized trial","volume":"31","author":"Gourgou-Bourgade","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2018.09.029_bib25","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/bjc.2017.67","article-title":"Quality-adjusted survival with combination nal-IRI+5-FU\/LV vs 5-FU\/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis","volume":"116","author":"Pelzer","year":"2017","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2018.09.029_bib26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11136-005-1579-7","article-title":"Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data","volume":"15","author":"Revicki","year":"2006","journal-title":"Qual Life Res"},{"issue":"23","key":"10.1016\/j.ejca.2018.09.029_bib27","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","article-title":"Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial","volume":"32","author":"Oettle","year":"2014","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2018.09.029_bib28","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1016\/j.ejca.2018.09.029_bib29","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","article-title":"Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial","volume":"29","author":"Loehrer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.029_bib30","series-title":"Poster presented at the European Society for Medical Oncology Annual Congress","author":"Hubner","year":"2016"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918313996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918313996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:22:48Z","timestamp":1760732568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918313996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":30,"alternative-id":["S0959804918313996"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.029","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}